TRTHIRU_Col.JPG

Ramachandran “TR” Thirucote, Ph.D.

 Co-founder & CEO

TR is the Co-Founder and CEO of LIPAC Oncology and TesoRx Pharma. TR has more than 30 years of experience in the design, development and launch of innovative biopharmaceutical products ranging from tablets and capsules to injectable and oral formulations, as well as ointments, creams and nasal drug delivery systems. Prior to founding TesoRx Pharma he held executive leadership positions at a variety of companies, focusing on the strategic development and commercialization of pharmaceutical products. Most recently he developed and managed an innovative virtual company model at ROXRO Pharma where he brought the drug-device combination SprixTM from early development to FDA approval. Prior to that, TR designed and launched a strategic program for the development of pharmaceutical products for private start-up companies at Stanford Research Institute. He also successfully led the oncology pipeline at Agouron Pharmaceuticals, resulting in a more than $2 billion acquisition of the company by Pfizer. At Thermedics, TR spearheaded the development of a high profile, trauma reducing anti-infective wound dressing for the Department of Defense. TR started his career with ASTRA-IDL in India, where he implemented quality design systems for manufacturing. TR attended the Massachusetts College of Pharmacy and Health Sciences where he earned a doctoral degree in Industrial Pharmacy, as well as Masters and Bachelors degree in Pharmaceutical Sciences. TR is a published scientist, an active consultant to the U.S. National Institutes of Health, and a member of the Special Emphasis Review Panel for the National Institute of Allergy and Infectious Diseases.


Michael headshot.jpg

Michael G Oefelein MD, FACS

co-founder & Chief Medical Officer

Michael is the Co-Founder and Chief Medical Officer at LIPAC Oncology and TesoRx Pharma. Michael is a board certified physician and a Fellow of the American College of Surgeons with more than 15 years of experience in the pharmaceutical and medical device industries with a focus on dermatology, urology, oncology, ophthalmology and plastic and bariatric surgery. Prior to joining TesoRx Pharma in 2014, Michael held leadership positions at Allergan and Digirad where he brought multiple drugs and devices from the laboratory to market including genitourinary oncology drugs Degarelix, Zometa and Apaziquone; non-oncology drugs Levaquin, Botox, Noctiva/Serenity-120; and devices Seriscaffold, breast implants, HA-fillers and surgical navigation systems. As a key opinion leader Michael has authored almost 100 peer reviewed publications, delivered scientific presentations at a variety of venues, led advisory boards, and designed and executed clinical trials for purposes ranging from registration trials to safety and pharmacoeconomic research. Michael holds multiple patents for his inventions.  Michael started his career in academia as an assistant professor of Urology and Oncology at the Ireland Cancer Center-Case Western Reserve University. Michael earned his undergraduate degree from the University of Rochester and went on to earn his medical degree  from Case Western Reserve University and his post-graduate degree in Surgery and Urology from Northwestern University. In addition to maintaining a private practice, Michael is an active member of numerous medical societies including the Society of Urological Oncology; Society of Urodynamics, Female Pelvic Medicine, & Urogenital Reconstruction; American Urological Association; and the American College of Surgeons and Laparoscopic Surgeons.


WAR_Square.png

Willem A Robberts

co-founder & President

Will is the Co-Founder and President of LIPAC Oncology and TesoRx Pharma. Will has more than 20 years of experience in finance and operational excellence in healthcare, software and technology companies. Prior to founding TesoRx Pharma he held executive leadership positions at a variety of companies, growing the businesses and successfully executing mergers and acquisitions. Most recently he managed more than 50 offices and more than 1,000 employees at Esquire Deposition Solutions, where he worked on the restructuring and ultimate sale of the company to Bayside Capital. Prior to that, Will served as President of LiveNote, where he grew the business to become the market leader in litigation software and sold it to Thomson Reuters. He also successfully sold AccountMate Software to Sage Accounting. Will started his career with KPMG in South Africa where he was first involved in international business working on landmark transactions in a variety of sectors. Will attended the University of Johannesburg where he earned degrees in Business Communications, Accounting and Management. Will serves on the Board of several pharmaceutical and technology companies and is passionate about providing solutions for patients living with unmet needs.


Shigeo photo.jpg

Shigeo Horie M.D., Ph.D.

International Advisor

Dr. Shigeo Horie is professor and chairman of Juntendo University Graduate School of Medicine. Shigeo is a key opinion leader in urology and oncology and has served as a TesoRx special advisor since 2016. He graduated from the University of Tokyo in 1985 and did his research and clinical fellowship at the UT Southwestern medical center in Dallas. Shigeo joined the faculty of the University of Tokyo, National Cancer Center Hospital, and Kyorin University before becoming the chairman of the Department of Urology of Teikyo University in 2003.

In 2012, Shigeo was appointed as the chairman of the Department of Urology of Juntendo University. He specialized in uro-oncology, urinary dysfunction, and Men’s Health and is considered the leading robotic surgeon in Asia. He published more than 150 peer-reviewed papers.